75 related articles for article (PubMed ID: 24858650)
1. Extravirologic modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc.
Ermocida A; Mengoni F; Sauzullo I; Rossi R; Ajassa C; Lichtner M; Mastroianni CM; Vullo V
New Microbiol; 2014 Apr; 37(2):225-9. PubMed ID: 24858650
[TBL] [Abstract][Full Text] [Related]
2. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy.
Romero-Sánchez MC; Alvarez-Ríos AI; Bernal-Morell E; Genebat M; Vera F; Benhnia MR; Bravo-Urbieta J; Galera-Peñaranda C; de Pablo-Bernal RS; Abad-Carrillo MA; Leal M; Ruiz-Mateos E;
Antiviral Res; 2014 Nov; 111():26-32. PubMed ID: 25173576
[TBL] [Abstract][Full Text] [Related]
4. Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.
Bigoloni A; Gianotti N; Spagnuolo V; Galli L; Nozza S; Cossarini F; Salpietro S; Carini E; Piatti P; Vinci C; Lazzarin A; Castagna A
AIDS; 2012 Sep; 26(14):1837-40. PubMed ID: 22739393
[TBL] [Abstract][Full Text] [Related]
5. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
De Luca A; Di Giambenedetto S; Maserati R; Gianotti N; Narciso P; Antinori A; Di Perri G; Prosperi MC; Baldanti F; Micheli V; Zazzi M; Perno CF; Santoro MM; ;
Antivir Ther; 2011; 16(4):489-97. PubMed ID: 21685536
[TBL] [Abstract][Full Text] [Related]
6. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.
Arberas H; Guardo AC; Bargalló ME; Maleno MJ; Calvo M; Blanco JL; García F; Gatell JM; Plana M
J Antimicrob Chemother; 2013 Mar; 68(3):577-86. PubMed ID: 23152485
[TBL] [Abstract][Full Text] [Related]
7. Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
Nozza S; Galli L; Bigoloni A; Gianotti N; Spagnuolo V; Carbone A; Chiappetta S; Ripa M; Tambussi G; Lazzarin A; Castagna A
New Microbiol; 2014 Apr; 37(2):145-51. PubMed ID: 24858641
[TBL] [Abstract][Full Text] [Related]
8. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
[TBL] [Abstract][Full Text] [Related]
9. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
10. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
[TBL] [Abstract][Full Text] [Related]
11. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
12. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
[TBL] [Abstract][Full Text] [Related]
13. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
14. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
MacArthur RD; Novak RM
Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
[TBL] [Abstract][Full Text] [Related]
15. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Hunt JS; Romanelli F
Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
[TBL] [Abstract][Full Text] [Related]
18. Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues.
Fletcher P; Herrera C; Armanasco N; Nuttall J; Shattock RJ
AIDS Res Hum Retroviruses; 2016 Apr; 32(4):334-8. PubMed ID: 26711323
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.
Dezzutti CS; Yandura S; Wang L; Moncla B; Teeple EA; Devlin B; Nuttall J; Brown ER; Rohan LC
Pharm Res; 2015 Nov; 32(11):3768-81. PubMed ID: 26078001
[TBL] [Abstract][Full Text] [Related]
20. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Cahn P; Fourie J; Grinsztejn B; Hodder S; Molina JM; Ruxrungtham K; Workman C; Van De Casteele T; De Doncker P; Lathouwers E; Tomaka F
AIDS; 2011 Apr; 25(7):929-39. PubMed ID: 21346512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]